Back to Search
Start Over
Synthesis and in vitro preliminary evaluation of prostate-specific membrane antigen targeted upconversion nanoparticles as a first step towards radio/fluorescence-guided surgery of prostate cancer
- Source :
- Journal of materials chemistry B, Journal of materials chemistry B, Royal Society of Chemistry, 2021, 9, pp.7423-7434. ⟨10.1039/D1TB00777G⟩, Journal of materials chemistry B, Royal Society of Chemistry, In press, ⟨10.1039/D1TB00777G⟩, Journal of materials chemistry B, Royal Society of Chemistry, 2021, ⟨10.1039/d1tb00777g⟩, Journal of materials chemistry B, 2021, 9, pp.7423-7434. ⟨10.1039/D1TB00777G⟩
- Publication Year :
- 2021
- Publisher :
- Royal Society of Chemistry (RSC), 2021.
-
Abstract
- International audience; Over the last decade, upconversion nanoparticles (UCNP) have been widely investigated in nanomedicine due to their high potential as imaging agents in the near-infrared (NIR) optical window of biological tissues. Here, we successfully develop active targeted UCNP as potential probes for dual NIR-NIR fluorescence and radioactive-guided surgery of prostate-specific membrane antigen (PSMA)(+) prostate cancers. We designed a one-pot thermolysis synthesis method to obtain oleic acid-coated spherical NaYF4:Yb,Tm@NaYF4 core/shell UCNP with narrow particle size distribution (30.0 ± 0.1 nm, as estimated by SAXS analysis) and efficient upconversion luminescence. Polyethylene glycol (PEG) ligands bearing different anchoring groups (phosphate, bis- and tetra-phosphonate-based) were synthesized and used to hydrophilize the UCNP. DLS studies led to the selection of a tetra-phosphonate PEG(2000) ligand affording water-dispersible UCNP with sustained colloidal stability in several aqueous media. PSMA-targeting ligands (i.e., glutamate-urea-lysine derivatives called KuEs) and fluorescent or radiolabelled prosthetic group were grafted onto the UCNP surface by strain-promoted azide-alkyne cycloaddition (SPAAC). These UCNP, coated with 10 or 100% surface density of KuE ligands, did not induce cytotoxicity over 24 h incubation in LNCaP-Luc or PC3-Luc prostate cancer cell lines or in human fibroblasts for any of the concentrations evaluated. Competitive binding assays and flow cytometry demonstrated the excellent affinity of UCNP@KuE for PSMA-positive LNCaP-Luc cells compared with non-targeted UCNP@CO2H. Furthermore, the binding of UCNP@KuE to prostate tumour cells was positively correlated with the surface density of PSMA-targeting ligands and maintained after 125I-radiolabelling. Finally, a preliminary biodistribution study in LNCaP-Luc-bearing mice demonstrated the radiochemical stability of non-targeted [125I]UCNP paving the way for future in vivo assessments.
- Subjects :
- Biodistribution
medicine.medical_specialty
[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imaging
[SDV]Life Sciences [q-bio]
Biomedical Engineering
[SDV.CAN]Life Sciences [q-bio]/Cancer
[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine
02 engineering and technology
Polyethylene glycol
Upconversion nanoparticles
[SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology
[SDV.IB.MN] Life Sciences [q-bio]/Bioengineering/Nuclear medicine
optical imaging
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
[SDV.CAN] Life Sciences [q-bio]/Cancer
In vivo
PEG ratio
PSMA
Glutamate carboxypeptidase II
medicine
General Materials Science
Cytotoxicity
[CHIM.MATE] Chemical Sciences/Material chemistry
Chemistry
[CHIM.MATE]Chemical Sciences/Material chemistry
General Chemistry
General Medicine
prostate cancer
021001 nanoscience & nanotechnology
[SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology
Fluorescence
Surgery
[SDV.IB.IMA] Life Sciences [q-bio]/Bioengineering/Imaging
SPECT
030220 oncology & carcinogenesis
Nanomedicine
0210 nano-technology
Subjects
Details
- ISSN :
- 20507518 and 2050750X
- Volume :
- 9
- Database :
- OpenAIRE
- Journal :
- Journal of Materials Chemistry B
- Accession number :
- edsair.doi.dedup.....e5d03c56f5d9817cf8b45e254b08f614